Some visit links earn us a commission.
Quick verdict
Medvi is the better pick for most patients on overall scoring. Medvi runs a compounded-semaglutide and tirzepatide model at flat monthly pricing, with no lock-in and rapid intake. Comparable to Henry Meds and Mochi on price; less established clinical depth than Form Health or Knownwell. Best fit for cash-pay patients who want predictable monthly cost with minimal friction.
That said, Embla wins on specific dimensions. Embla is the closest thing the US market has to a Noom-meets-Calibrate hybrid that actually leans into the medication. Heavy behavioral coaching, branded-first prescribing, structured 12-month curriculum. Best for buyers who want the program to do half the work.
Side-by-side
| Medvi | Embla | |
|---|---|---|
| Starts from | $299/mo (incl. medication) | $249/mo (+ med separate) |
| Monthly cost gap | Medvi is $70/mo cheaper than Embla | |
| Lock-in | Month-to-month | 12-mo lock-in |
| Time to prescription | 2 days | 7 days |
| Consultation type | Asynchronous | Live |
| Affiliate network | Direct | Impact |
Score by dimension
Scores out of 10, equal-weighted across five dimensions. How we score. The winner of each dimension is highlighted.
| Medvi | Embla | |
|---|---|---|
| Pricing transparency | 8/10 | 4/10 |
| Cancellation terms | 8/10 | 7/10 |
| Onboarding experience | 7/10 | 6/10 |
| Medication options | 7/10 | 7/10 |
| Member reviews | 9/10 | 9.2/10 |
When to choose Medvi
Best for flat compounded with no lock-in
Cash-pay patients who want flat predictable compounded GLP-1 pricing with no lock-in and same-week onboarding. Strong fit if you've taken GLP-1 before and want a simple ongoing prescription channel.
Medvi wins on pricing transparency, cancellation terms, onboarding experience and runs $70/mo cheaper than Embla at the entry tier ($179 vs $249). Over a year that's $840 you keep. The caveat: Insurance-pathway shoppers, patients with multiple comorbidities needing clinical depth or anyone wanting branded Wegovy or Zepbound through standard PA. Note also: Compounded GLP-1 carries 503A regulatory exposure; see compounded callout
When to choose Embla
Best for structured behavior support
Patients who tried meds-only and bounced, and want a structured behavior program alongside GLP-1.
Embla wins on member reviews on the dimensional scoring. The caveat: Buyers who only want the script and find coaching content patronizing.
If cost is your main filter
Medvi is the cheaper monthly: $179 all-in vs $249 for Embla. That's $70 a month or $840a year. The 12-month math matters most if you're planning to maintain on GLP-1 long-term. If you're running a 3-month trial, the $210 delta is small against the cost of stopping early on the wrong dose. Insurance changes the picture: if either program runs prior auth and your plan covers Wegovy or Zepbound, branded with copay can beat both cash-pay totals.
If lock-in is your main filter
Medvi (month-to-month) and Embla (12-mo lock-in) sit at different cancellation tiers. If you're first-time on a GLP-1 and unsure how you'll tolerate it, Medvi's easier cancellation is the safer trial.
FAQ
Is Medvi cheaper than Embla?
Can I switch from Medvi to Embla mid-treatment?
Which program has better member feedback?
Read the full reviews
All head-to-head comparisons → · Full chart → · Cost guide · Programs guide
